Ambalal Sarabhai Enterprises Limited
BSE: AMBALALSA
Prev Close
39.36
Open Price
39.25
Volume
119,516
Today Low / High
39 / 41
52 WK Low / High
34.11 / 59.99
Range
37 - 41
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 39.43, reflecting a change of 0.07 (0.17785%). The expected target range on the BSE is 37 - 41. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.
Ambalal Sarabhai Enterprises Limited Graph
Ambalal Sarabhai Enterprises Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Ambalal Sarabhai Enterprises Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 39.43, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 39.43 | 39.82 | 35.84 - 43.81 |
| 40.22 | 32.17 - 48.26 | ||
| 40.61 | 28.43 - 52.80 | ||
| Bearish Scenario | 39.43 | 39.04 | 35.13 - 42.94 |
| 38.64 | 30.91 - 46.37 | ||
| 38.25 | 26.77 - 49.72 |
Overview of Ambalal Sarabhai Enterprises Limited
ISIN
INE432A01017
Industry
Medical - Pharmaceuticals
Vol.Avg
196,734
Market Cap
3,021,651,019
Last Dividend
0
Official Website
IPO Date
2000-05-04
DCF Diff
78.36
DCF
-39
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 172.94 Cr | 102.57 Cr | 70.38 Cr | 0.4069 | 0.22 Cr | 4.98 Cr | 43.68 Cr | 5.68 Cr | 0.74 | 17.06 Cr | 0.0328 |
| 2023-03-31 | 169.74 Cr | 107.43 Cr | 62.31 Cr | 0.3671 | 0.11 Cr | 4.77 Cr | 6.39 Cr | 11.45 Cr | 1.45 | 21.33 Cr | 0.0674 |
| 2022-03-31 | 195.07 Cr | 119.10 Cr | 75.97 Cr | 0.3894 | 0.08 Cr | 4.67 Cr | 21.39 Cr | 47.22 Cr | 6.16 | 52.13 Cr | 0.2421 |
| 2021-03-31 | 162.77 Cr | 103.48 Cr | 59.29 Cr | 0.3642 | 0.15 Cr | 4.38 Cr | 0.56 Cr | 29.36 Cr | 3.83 | 22.78 Cr | 0.1804 |
| 2020-03-31 | 131.32 Cr | 82.37 Cr | 48.95 Cr | 0.3727 | 0.00 Cr | 4.93 Cr | -4.70 Cr | 14.06 Cr | 1.83 | 22.49 Cr | 0.1071 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 10.78 Cr | 250.23 Cr | 113.09 Cr | 137.1328 Cr | 46.11 Cr | 35.37 Cr | 16.18 Cr | 63.04 Cr | 4.45 Cr | 0.00 Cr | 34.99 Cr | 102.3177 Cr |
| 2023-03-31 | 10.13 Cr | 245.74 Cr | 114.82 Cr | 130.9231 Cr | 41.93 Cr | 31.80 Cr | 17.43 Cr | 64.28 Cr | 5.82 Cr | 0.00 Cr | 38.50 Cr | 95.1738 Cr |
| 2022-03-31 | 12.10 Cr | 230.50 Cr | 110.65 Cr | 119.8665 Cr | 26.75 Cr | 14.65 Cr | 15.14 Cr | 45.41 Cr | 5.22 Cr | -1.88 Cr | 36.79 Cr | 105.4681 Cr |
| 2021-03-31 | 14.74 Cr | 210.05 Cr | 136.16 Cr | 73.8981 Cr | 27.94 Cr | 13.20 Cr | 15.97 Cr | 33.06 Cr | 4.33 Cr | -2.55 Cr | 28.08 Cr | 128.5411 Cr |
| 2020-03-31 | 12.79 Cr | 186.45 Cr | 141.69 Cr | 44.7674 Cr | 30.78 Cr | 18.00 Cr | 16.45 Cr | 33.29 Cr | 4.33 Cr | -2.89 Cr | 19.06 Cr | 133.4654 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 2.2388 Cr | -1.1256 Cr | -2.9454 Cr | 1.6121 Cr | 0.6463 Cr | 10.7761 Cr | -3.1052 Cr | 5.6807 Cr | 1.6791 Cr | 0.0000 Cr | 1.2277 Cr |
| 2023-03-31 | 5.7245 Cr | -16.7818 Cr | 9.0854 Cr | -14.9438 Cr | -1.9719 Cr | 10.1298 Cr | -20.6683 Cr | 14.8252 Cr | 14.5198 Cr | 0.0000 Cr | -2.2819 Cr |
| 2022-03-31 | 11.4721 Cr | 5.0768 Cr | -19.1857 Cr | -4.2391 Cr | -2.6368 Cr | 12.1017 Cr | -15.7112 Cr | 54.1935 Cr | -2.0183 Cr | 0.0000 Cr | 0.8247 Cr |
| 2021-03-31 | -2.2989 Cr | 10.0898 Cr | -5.8401 Cr | -4.7582 Cr | 1.9508 Cr | 14.7385 Cr | -2.4593 Cr | 32.5407 Cr | -2.3562 Cr | 0.0000 Cr | 0.4731 Cr |
| 2020-03-31 | -6.8794 Cr | 16.8876 Cr | -14.2155 Cr | -10.5581 Cr | -4.2073 Cr | 12.7877 Cr | -3.6787 Cr | 14.9359 Cr | -10.2486 Cr | 0.0000 Cr | -1.4616 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 45.97 Cr | 27.56 Cr | 18.41 Cr | 0.4005 | -1.69 Cr | 2.23 Cr | 0.29 | 5.06 Cr | 0.0485 |
| 2024-09-30 | 44.70 Cr | 23.80 Cr | 20.91 Cr | 0.4677 | 1.52 Cr | 2.62 Cr | 0.34 | 5.34 Cr | 0.0586 |
| 2024-06-30 | 40.70 Cr | 31.41 Cr | 9.28 Cr | 0.2281 | 10.26 Cr | 0.35 Cr | 0.05 | 3.14 Cr | 0.0085 |
| 2024-03-31 | 54.35 Cr | 38.21 Cr | 16.13 Cr | 0.2968 | 5.48 Cr | 8.29 Cr | 1.18 | 10.52 Cr | 0.1525 |
| 2023-12-31 | 43.11 Cr | 32.28 Cr | 10.84 Cr | 0.2514 | 1.40 Cr | 1.18 Cr | 0.15 | 3.89 Cr | 0.0274 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 3.39 Cr | 27.02 Cr | 30.41 Cr | 0.00 Cr | 25.54 Cr | 128.61 Cr | 64.07 Cr | 260.46 Cr | 120.07 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 26.72 Cr | 0.00 Cr | 0.00 Cr | 26.72 Cr | 0.00 Cr | 0.00 Cr | -137.14 Cr |
| 2024-03-31 | 32.90 Cr | 27.08 Cr | 32.90 Cr | 30.45 Cr | 16.18 Cr | 118.54 Cr | 63.04 Cr | 250.23 Cr | 113.09 Cr |
| 2023-12-31 | -22.36 Cr | 44.71 Cr | 22.36 Cr | 0.00 Cr | 0.00 Cr | 22.36 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 4.88 Cr | 28.77 Cr | 33.65 Cr | 23.90 Cr | 21.58 Cr | 109.93 Cr | 64.24 Cr | 240.24 Cr | 113.20 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 0.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 8.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 1.18 Cr | 2.27 Cr | 0.00 Cr | 0.00 Cr | 2.27 Cr | 24.62 Cr | 22.36 Cr | 0.00 Cr | 2.27 Cr |
| 2023-09-30 | 1.08 Cr | 1.08 Cr | 0.00 Cr | 0.00 Cr | 1.08 Cr | 22.36 Cr | 21.27 Cr | 0.00 Cr | 1.08 Cr |
| 2023-06-30 | -4.87 Cr | -4.87 Cr | 0.00 Cr | 0.00 Cr | -17.88 Cr | -4.87 Cr | 13.01 Cr | 0.00 Cr | -4.87 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹820.60 | ₹98,220,756,898.00 | ₹85,846.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born: 1948
Gender: female
Year Born: 1959
Gender: male
Year Born: 1970
Gender: female
Year Born:
Gender: male
Year Born: 1947
FAQs about Ambalal Sarabhai Enterprises Limited
The CEO is Mr. Kartikeya Vikram Sarabhai M.A..
The current price is ₹39.43.
The range is ₹34.11-59.99.
The market capitalization is ₹302.17 crores.
The P/E ratio is 22.50.
The company operates in the Healthcare sector.
Overview of Ambalal Sarabhai Enterprises Limited (ISIN: INE432A01017) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹302.17 crores and an average daily volume of 196,734 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.